ArticleNeuro-oncology advances
Outcomes of H3K27M-altered diffuse midline glioma adult Chinese patients and real-world experience with German-sourced ONC201 targeted therapy: A multi-center study in Hong Kong.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A novel dopamine-receptor small molecule inhibitor, ONC201, was observed to elicit a treatment response in patients with H3K27M-altered diffuse midline gliomas (DMG). Given restricted access to this therapy, an alternative formulation from Germany (GsONC201) was made available by compassionate means. We describe the treatment outcomes of these patients and our experience with GsONC201. Methods: This was a multicenter retrospective study of adult Chinese patients with histologically confirmed H3K727M-altered DMG. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival, the observed response rate (ORR) at 3 months after radiotherapy and GsONC201-associated adverse effects. Results: Twenty-seven patients, median age of 40 years (range: 31-52), were identified. Fifty-two percent (14/27) of tumors arose from the thalamus followed by the pons (22%, 6). Eighty-five percent (23/27) of patients received standard-of-care (SOC) fractionated radiotherapy. Thirty-seven percent (10/27) of patients received GsONC201 of which 80% (8/10) started it as first-line monotherapy after SOC. The mOS of the entire cohort was 17.4 months (IQR: 12.1-30.0). GsONC201 + SOC patients (8) had a mOS of 18.9 months (IQR: 11.3-54.4) compared to 16.0 months (IQR: 12.5-27.6) for SOC-alone patients (13, Conclusion: This is the first real-world study to review the outcomes of first-line imipridone-class agent therapy in adult Chinese DMG patients. GsONC201 was well-tolerated, but its effect on OS remains unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.